A 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial of lumiracoxib (COX189) 100 mg o.d. in patients with primary hip osteoarthritis using celecoxib (200 mg o.d.) as a positive control

Trial Profile

A 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial of lumiracoxib (COX189) 100 mg o.d. in patients with primary hip osteoarthritis using celecoxib (200 mg o.d.) as a positive control

Completed
Phase of Trial: Phase III

Latest Information Update: 18 May 2012

At a glance

  • Drugs Celecoxib; Lumiracoxib
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 13 Jun 2007 Primary endpoint 'Pain-intensity' has been met.
    • 13 Jun 2007 Primary endpoint 'Functional-clinical-response' has been met.
    • 13 Jun 2007 Primary endpoint 'Disease-activity-score' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top